Topical Anti Inflammatory Treatment Therapeutics
1. Filsuvez patent expiration
Treatment: Use of birch triterpenes for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11266660 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(12 years from now) | |
| US9827214 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(4 years from now) | |
| US9352041 | CHIESI | Use of an oleogel containing triterpene for healing wounds |
Nov, 2030
(4 years from now) | |
| US12268695 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(12 years from now) | |
| US11083733 | CHIESI | Betulin-containing birch bark extracts and their formulation |
Jan, 2039
(12 years from now) | |
| US8828444 | CHIESI | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
Jun, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2028 |
| Orphan Drug Exclusivity(ODE-460) | Dec 18, 2030 |
Drugs and Companies using BIRCH TRITERPENES ingredient
NCE-1 date: 19 December, 2027
Market Authorisation Date: 18 December, 2023
Dosage: GEL
More Information on Dosage
FILSUVEZ family patents
